Changes in Eye Pressure and Anterior Chamber Depth With Oral Endothelin Antagonist Therapy
| Status: | Recruiting |
|---|---|
| Conditions: | High Blood Pressure (Hypertension), Ocular |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Ophthalmology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 11/18/2012 |
| Start Date: | March 2007 |
| Contact: | Tim Byrne |
| Email: | tim.byrne@uchsc.edu |
| Phone: | 720-848-5051 |
The Effect of a Systemic Non-Selective Endothelin Antagonist on Intraocular Pressure and Anterior Depth in Pulmonary Hypertension Patients.
There is growing evidence that a cause of glaucoma is linked to circulatory problems and
poor auto-regulation of blood flow to the optic nerve. Pulmonary hypertension (PH)is a
disease characterized by low oxygen levels in the blood and altered blood circulation. The
decrease in oxygen delivery to the optic nerve could lead to the loss of nerve fiber
layer(NFL)in the retina and the resulting visual field compromise. This situation is
characteristic of glaucoma. The ability to identify NFL thinning early could lead to
earlier diagnosis of glaucoma and more effective treatment to limit dysfunction from visual
field loss.
We hypothesize that the rate of structural damage to the NFL, a feature of glaucoma, is
higher in patients with PH than expected in healthy populations lacking this disease.
Inclusion Criteria:
- diagnosed with pulmonary hypertension
- between the ages of 18 and 80 years
- ability to undergo the various ocular exams.
Exclusion Criteria:
- patients with other diseases that could affect the nerve fiber layer
- specials populations; ie children, pregnancy, lactating females, prisoners
We found this trial at
1
site
Click here to add this to my saved trials
